CD30 CAR-T for relapsed or refractory CD30+ lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 to 80 years old.
- Your lymphoma tests positive for CD30 (a protein on the cancer cells).
- You have at least one tumor that can be seen on a scan.
- You have tried or cannot have a stem cell transplant using your own cells, or a drug called brentuximab (Adcetris).
- Your organs (like liver, kidneys, heart, and lungs) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
This trial tests a new cell therapy (CD30 CAR T-cells) given after a stem cell transplant to treat Hodgkin lymphoma that has not responded well. It may help your body's immune cells fight the cancer more effectively.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This trial tests a new treatment that uses your own immune cells, modified to find and attack cancer cells that have a protein called CD30 on them. It may be an option if your lymphoma has come back or hasn't improved with other treatments.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.